Rimonabant - CAS 168273-06-1

Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.

Acyltransferase, Antibacterial, Cannabinoid Receptor

Microbiology/Virology, GPCR/G Protein, Metabolism

168273-06-1

0.9991

C22H21Cl3N4O

463.79

Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1

-20°C

Ice Packs

Small Compound